Select Vaccines signs agreement to develop Hep C test
Thursday, 25 March, 2004
Select Vaccines (ASX: SLT) has signed a materials transfer agreement (MTA) with a multinational biotechnology company to access materials it will use to accelerate the development of its hepatitis C rapid diagnostic test.
"It's one in a series of MTAs which will put us in the best possible position to have a rapid test that works with a number of rapid systems in the marketplace," said CEO Dr Martin Soust.
Soust said the agreement would cut at least three months off the timeframe required to develop the point-of-care test, and would allow the company to compare multiple rapid systems concurrently.
The MTA also contains the provision that the supplier company will be able to exercise rights to license or on-license any IP that arises from successful development.
Preventing neural graft rejection in Parkinson's patients
Researchers have engineered a way to fool the immune system into accepting neural grafts as part...
Retinal health linked to dementia risk, study shows
Researchers have discovered that the blood vessels at the back of the eye — called retinal...
Pancreatic cancer hijacks metabolism switch to help it spread
Pancreatic cancer hijacks a molecule known for regulating physiological processes, such as food...
